SCHEMBL3979806

SCHEMBL3979806

CC(C)c1cc(Br)ccc1I

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.46
GABRB1 P18505 3/20 0.46
GABRB2 P47870 2/20 0.37
CYP2A6 P11509 2/20 0.34
FABP4 P15090 2/20 0.34
ALDH1A1 P00352 2/20 0.33
HTT P42858 1/20 0.33
MAPT P10636 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
LPAR1 Q92633 1/20 0.32
HPGD P15428 2/20 0.30
MEN1 O00255 1/20 0.30
RAB9A P51151 1/20 0.30
KMT2A Q03164 1/20 0.30
LMNA P02545 2/20 0.30
SLC6A2 P23975 2/20 0.30
HTR2B P41595 2/20 0.30
TRPA1 O75762 1/20 0.30
CHRM1 P11229 1/20 0.30
ADRA1A P35348 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31370930 1.00 GABRA1 (0.46) GABRA1GABRB1GABRB2CYP2A6FABP4
SCHEMBL31064616 0.83 GABRA1 (0.39) GABRA1GABRB1GABRB2HPGDMEN1
SCHEMBL16957600 0.83 GABRA1 (0.34) GABRA1GABRB1
SCHEMBL16936177 0.82 GABRA1 (0.41) GABRA1GABRB1GABRB2CYP2A6FABP4
SCHEMBL15459963 0.78 GABRA1 (0.52) GABRA1GABRB1GABRB2CYP2A6ALDH1A1
SCHEMBL29173558 0.77 CYP2A6 (0.30) CYP2A6
SCHEMBL13818840 0.76 GABRA1 (0.50) GABRA1GABRB1GABRB2HPGDLMNA
SCHEMBL12263566 0.76 GABRA1 (0.50) GABRA1GABRB1CYP2A6FABP4ALDH1A1
SCHEMBL12656507 0.74 TRPA1 (0.50) GABRA1GABRB1GABRB2CYP2A6LMNA
SCHEMBL31438459 0.74 LMNA (0.41) GABRA1GABRB1GABRB2FABP4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246950-A1 Anilino-Pyrazole Derivatives, Compositions and Methods Thereof Ensem Therapeutics (US) 2024-07-25 US disclosed
WO-2015111943-A1 ORGANIC COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME 주식회사 두산 2015-07-30 WO disclosed
WO-2015111943-A1 ORGANIC COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME 주식회사 두산 2015-07-30 WO disclosed
WO-2009055674-A1 PYRROLOPYRIMIDINE ALKYNYL COMPOUNDS AND METHODS OF MAKING AND USING SAME TARGEGEN INC. (US) 2009-04-30 WO disclosed
WO-2009055674-A1 PYRROLOPYRIMIDINE ALKYNYL COMPOUNDS AND METHODS OF MAKING AND USING SAME TARGEGEN INC. (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246950-A1 Anilino-Pyrazole Derivatives, Compositions and Methods Thereof CDK2, CDK3, CDK4 GABRA1 4707/4885GABRB1 4637/4885GABRB2 4551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.